Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose

Affimed NV AFMD has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE) AFM13.

  • Eighteen patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas were treated with the combination of cbNK cells pre-complexed with AFM13. 
  • 16 of 18 patients had achieved an objective response, with seven complete responses (CR) and nine partial responses (PR). 
  • 11 of 12 patients treated at the recommended phase 2 dose level of 108 cbNK cells per kg had Hodgkin Lymphoma. 
  • In this cohort of patients treated at the recommended phase 2 dose, 100% responded after the first treatment cycle with five CRs and seven PRs. 
  • Treatment was well tolerated with five reported cases of transient infusion-related reactions after the monotherapy infusions of AFM13. 
  • There were no serious adverse events such as cytokine release syndrome, immune cell-associated neurotoxicity syndrome, or graft-versus-host disease.
  • Price Action: AFMD shares are down 2.68% at $6.54 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareSmall CapMoversTrading IdeasGeneralBriefslymphomaNon Hodgkin LymphomaPhase 1 TrialPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!